Philip Morris International Inc. (PM) Earnings Call Transcript & Summary

February 8, 2024

New York Stock Exchange US Consumer Staples Tobacco earnings 79 min

Earnings Call Speaker Segments

James Bushnell

executive
#1

Good day, and thanks for being here. We put out a press release earlier today with full details about how we performed in the fourth quarter and across all of 2023. You can find that release on our site, www.pmi.com. For definitions — including what counts as a smoke-free product, plus adjustments, other calculations, and reconciliations tying the non-GAAP financial measures mentioned in this presentation to the closest U.S. GAAP equivalents — along with extra net revenue figures, those are in Exhibit 99.2 of the company's Form 8-K dated February 8, 2024, and also posted on our Investor Relations website. Remarks made today include forward-looking statements and projections regarding future results. Please look at the forward-looking and cautionary statements disclosure in today's presentation and press release, which reviews the various factors that might make actual results differ materially from projections or forward-looking statements. Joining me now are Jacek Olczak, our Chief Executive Officer, and Emmanuel Babeau, our Chief Financial Officer. Jacek, the floor is yours.

Jacek Olczak

executive
#2

Thanks, James, and hello everybody. In 2023, PMI turned in yet another robust operating showing. We posted our third straight year of positive volumes along with high single-digit organic top line growth, powered by smoke-free products. During the fourth quarter, smoke-free products brought faster accretion to profitability, since our IQOS business generated meaningful 2023 operating leverage that offset a sizable drag from combustibles. I'm equally delighted to share that ZYN kept growing exceptionally well, and it wasn't part of organic metrics until mid-November. Notably, in Q4 smoke-free products accounted for almost 40% of total PMI net revenues and more than 40% of gross profit. Across the full year, smoke-free gross profit rose 19% organically, and we anticipate that smoke-free organic growth will speed up for net revenues as well as gross profit in 2024. In ZYN's first year inside PMI it grew extraordinarily, with U.S. pro forma volumes climbing more than 60% for the year and above 75% in quarter four. Oral smoke-free benefits both our smoke-free business and the group as a whole, as Swedish Match added 50 basis points of organic uplift to Q4 OI margins from just 50 days of the period. Our IQOS business keeps producing superb results, with 15% adjusted in-market sales growth for heated tobacco units that mirrors broad-based momentum across Europe, Japan, and emerging markets. The IQOS ILUMA rollout is essentially finished, and it now exists in 51 markets, covering more than 95% of IQOS geographies by volume once Russia and Ukraine are excluded. ILUMA's superior experience and design, paired with IQOS's strong premium brand equity and our unmatched commercial infrastructure, let IQOS outgrow the heat-not-burn category even though it holds a category share above 75%. Crucially, as Japan has shown us, the ILUMA launch acts as a multiyear growth driver, in line with earlier IQOS innovations. Despite solid commercial results, our 2023 combustible performance diluted margin, with very good pricing and a higher category share. That mirrors the considerable cost pressures in the category, geographic mix stemming from volume growth in lower margin markets lacking smoke-free products, and the effect of IQOS cannibalization. On top of that came the technical impact of third-party manufacturing in Indonesia and Ukraine. Although cost and currency headwinds weighed on our earnings in 2023, the strengthening growth and margin profile of smoke-free products positions us well to deliver sustainable growth and returns, currency included, in 2024 and beyond; during Q4 we hit several key transformation milestones. First, IQOS net revenues overtook Marlboro, making it the number one international nicotine brand on that measure. This shows how innovative smoke-free alternatives can switch adult smokers away from cigarettes and tackle the societal issue of combustible tobacco. It also proves our organization's capacity to build strong and sustainable brand equity. The same holds for ZYN, the fastest growing U.S. smoke-free brand, which turned in another outstanding Q4, highlighted by gains in category volume share, retail value share, and overall volumes. We're also pleased that smoke-free offerings now account for over half of our top line in 25 markets across both Q4 and the entire year; our goal is to hit 60 markets by 2030, fueling our ambition to push group net revenues beyond two-thirds. And finally, as I noted earlier, smoke-free products brought in more than 40% of total gross profit, with the adjusted gross margin rate for smoke-free beating combustibles in both the quarter and the year; it's encouraging to see more governments embrace tobacco harm reduction policies that promote reduced risk nicotine consumption over smoking, which is ultimately more sustainable for society. Still, plenty of work lies ahead. A sustainable business is essential for sustainable growth, and we keep earning growing recognition for our sustainability performance on the key product and operational topics for our company. PMI joined the Dow Jones Sustainability World Index for the first time, and made DJSI North America for the fourth year running. PMI also received a carbon disposal projects Triple A rating for the fourth year in a row. Now I'll pass it to Emmanuel to go over our results and outlook in greater detail.

Emmanuel Babeau

executive
#3

Thanks, Jacek. Starting with the top-line figures: we closed out the year on a strong note, with Q4 organic net revenue up 8.3%. That figure breaks down into 14% growth from smoke-free products — even though HTU shipment growth was slower because of comparison effects — plus 5% growth from combustibles. In both categories, pricing served as a powerful engine, and on the smoke-free side that pricing incorporates the effect of retail price hikes on HTUs. Swedish Match only entered our organic metrics as of November 12, yet it added 0.8 percentage points to Q4 organic top-line growth and, on a pro forma basis, expanded by an excellent 26%. Our organic operating profit increased by a solid 8%, and Swedish Match accounted for 2.2 points of that gain. As we had expected, Q4 margins were largely unchanged on an organic basis, and they were higher once the technical impacts Jacek mentioned are taken out. As a result, the company delivered another quarter of double-digit growth in currency neutral adjusted diluted EPS, reaching 12.2%. That result exceeded our earlier forecast, and ZYN's outstanding expansion was a standout factor behind it. So despite that solid result on a currency-neutral basis, our Q4 adjusted diluted EPS came in at $1.36, and it was hurt by a currency hit bigger than what we'd expected — that was $0.20. Within that number there's a $0.09 impact tied to the balance sheet under hyperinflationary accounting in Argentina, and that came after the peso was devalued in mid-December. This is the same kind of thing we talked about earlier for Q3 — it reflects the depreciation of monetary net assets that are denominated in pesos and are subject to capital controls. By its nature, it doesn't carry forward into future periods. Now, turning to the full year. Organic net revenues were up 7.8%, which makes it the third year in a row of high single-digit growth. Like in Q4, that reflects continued excellent IQOS momentum as well as strong combustible pricing. In 2023, Swedish Match, with ZYN at the forefront, grew pro forma net revenues in ex-currency terms by 20%. Organic operating income was up 3.7%, reflecting a tough first half that gave way to robust expansion in H2. During H2, we expanded both adjusted gross margins and operating income margins, thanks to strong momentum in smoke-free products. With accelerated device sales from the ILUMA rollout now in the base and sea freight to Japan resuming, the benefits of rising HTU volumes and continuous cost optimization are plainly evident. As expected, organic OI margins narrowed by 150 basis points across the full year, largely because of severe cost and supply chain pressures in H1. Like we mentioned in earlier quarters, the full-year margin picture carries a 40 basis point drag tied to how third-party manufacturing gets accounted for in Indonesia and Ukraine. That mostly comes down to the Indonesia excise tax gross up, roughly $250 million of growth in both net revenues and cost of sales. Combustibles headwinds haven't completely gone away, but our smoke-free segment is putting up great profit growth, and going forward our organic results will reflect the strong contributions from Swedish Match. We managed to offset inflationary pressure and keep funding investments by finding efficiencies. Across our whole operating cost structure, we delivered $100 million of incremental gross cost efficiencies in Q4, on top of $2.2 billion for 2021/2023 overall, which beat our $2 billion target. We're targeting an additional $2 billion across the next three years. Because of those positive factors, our currency neutral adjusted diluted EPS growth came in at a very strong plus 11%, which was above our earlier expectations. The $6.01 adjusted diluted EPS figure includes an unfavorable currency impact of $0.63, largely from the Japanese yen, Russian ruble, and the specific Argentine peso effects I mentioned before; more information is available on a slide in the appendix of this presentation. Now turning to volumes; we achieved shipment growth for a third consecutive year, and with room to spare, driven by a 15% increase for IQOS HTUs, together with resilient combustible performance. During the fourth quarter, products without smoke made up over 20% of PMI's overall volume. With growth in this segment expected to stay in the mid-teens or higher, we believe we're well positioned to continue expanding volumes over both the medium and long term. For 2023, HTU shipments reached 125.3 billion units, which fell at the bottom of the range we had targeted, owing to delayed introductions in Saudi Arabia and Taiwan, as well as softer-than-anticipated underlying growth in Russia and Ukraine. Regarding IQOS HTUs, we consider adjusted IMS to be the strongest measure of underlying growth, since it comes closest to consumer offtake. Adjusted in-market volumes and shipment growth both ended the full year at plus 15%, matching each other. HTU shipment growth of 6% in the fourth quarter mirrors trade inventory build-up during the prior year quarter, so the plus 14% adjusted IMS growth is a more dependable gauge of sustained strong growth momentum. Adjusted in-market sales rose by more than plus 17% for the year when Russia and Ukraine are excluded. To put that in context, during the two years prior to the war starting in 2022, these markets represented 23% of HTU shipment volumes and surpassed the company's growth rate by a considerable margin. Those smoke-free volume increases don't capture the impressive performance of our oral nicotine lineup, which ZYN leads — its shipment volumes climbed 23% in Q4 and 17% for 2023 on a pro forma basis. For cigarettes, shipments slipped just 1.4% in 2023, which was better than the 2.4% drop seen across the international category. Turning now to profits. After the unusual headwinds faced in H1, organic operating income growth picked up pace in H2, reaching 10%. We view that as a better reflection of the momentum underneath our business, and it lines up with the plus 8% to 10% CAGR target range we've set for 2024/2026. Now let's look at some of the main factors behind our operating income for the full year. In smoke-free products, gross profit grew organically by a very strong plus 19%, which pushed gross margins up by 340 basis points. That reflects some of the operating leverage from IQOS that I mentioned earlier, and we also got a major boost from Swedish Match oral nicotine over the final 50 days of Q4, which delivered organic operating profit growth of more than 50%. Because commercial expenses in smoke-free came in lower than the increase in net revenues, that's clearly an encouraging sign for 2024, since scale benefits and manufacturing optimization continue to work in our favor. Despite really strong pricing, combustible gross profits only edged up on an organic basis. A portion of that comes from the unfavorable geographic blend I mentioned before — steeper shipment drops in places with better margins, including Japan, as people who smoke cigarettes switch to smoke-free offerings, combined with better shipment patterns in areas carrying thinner margins where smoke-free items are scarce or not sold, such as Turkey. We also ran into substantial inflation affecting leaf, direct materials, and other production expenses. Higher leaf costs, whose inventory covers multiple harvest years, plus salaries, will likely continue through 2024 and should ease thereafter. Now, about Swedish Match — its first full year under PMI delivered outstanding performance, with adjusted pro forma currency neutral net revenues climbing 26% in Q4 and 20% for 2023. When we announced our bid for Swedish Match back in 2022, we aimed for a return on investment that would surpass our cost of capital inside five years. Thanks to ZYN's quicker-than-expected expansion, we're now confident that milestone will arrive much earlier. In the U.S., ZYN once again achieved remarkable results, as volumes rose 78% in Q4 and 62% across 2023.

Emmanuel Babeau

executive
#4

On a global level, we rolled out or brought back ZYN in 10 markets, exactly as we'd intended, while keeping our attention on establishing it as a worldwide brand. For U.S. cigars, 2023 delivered strong performance, with both net revenues and profits climbing; the main factor was solid pricing after an April hike, though this was partly counterbalanced by lower volumes stemming from rivals' delayed price moves and tough comparisons. ZYN kept up its outstanding momentum stateside in Q4, posting 15% growth over the prior quarter in 12-month rolling shipments. Even more striking, its share of category volume rose for a third straight quarter, hitting 72.8% — that's up plus 5.4 points versus a year earlier and plus 2 points from the previous quarter. Retail value share likewise climbed in the quarter, reaching 77.4%, which underscores ZYN's premium standing and exceptional brand equity. This quicker expansion once again mirrors a wide-ranging lift in store-level sales rates across the country and steady distribution gains, as the category draws strong interest from adult nicotine consumers thanks to its ease of use and enjoyable experience; we're now turning our attention to IQOS, beginning with user growth. As of December 31st, we estimate 28.6 million people were using IQOS, which marks an increase of 1.2 million users during the quarter and 3.7 million across the entire year — a pleasant speed-up relative to 2022. That covers meaningful gains in Japan and Europe, along with a wide array of other regions. ILUMA has now reached essentially every major market apart from Russia and Ukraine, with an estimated 17 million-plus adult users as of December 31, 2023; this mirrors existing IQOS users making the switch plus adult smokers being brought in; we anticipate ILUMA will fuel ongoing robust IQOS user growth throughout 2024 and afterward. Given how user estimates swing with the seasons and quarter-to-quarter volatility, we'll report this metric every six months from now on. With ZYN now part of our lineup, alongside a smaller yet expanding VEEV e-vapor operation, we also plan to give investors a fuller picture of our overall smoke-free user base. Turning next to IQOS in the Europe region, where smoke-free products accounted for over 45% of Q4 net revenues. Our Q4 adjusted HTU share rose by plus 1.2 points, reaching 9.6% of combined cigarette and HTU industry volume. A major factor is rising adoption of ILUMA, which around 90% of IQOS users in the region can now access following eight additional launches during the quarter. Within the EU, 11 markets representing close to 30% of regional IQOS volumes embraced the delegated directive to enforce a characterizing flavor prohibition on heated tobacco products and put clean-shelf rules in place during October. Though it's still early, we figure there's only a minor effect on offtake as consumers adapt, and likewise on trade inventory levels. In fact, adjusted IMS volumes keep showing very solid sequential gains and hit a record 12.4 billion units on a four-quarter moving average. That mirrors double-digit year-over-year improvement of plus 13% in Q4, even with no growth coming from Ukraine. Looking ahead, we anticipate that the rest of the EU markets will implement the characterizing flavor prohibition during 2024. We estimate that the consumer adjustment effect for a full year will be roughly 2 billion units, affecting both shipment and IMS, which works out to under 5% of regional volumes and under 2% of total PMI. That aligns with what we saw with earlier flavor restrictions, like the EU combustible ban that took effect in 2020. Drawing on early figures from the markets where the ban has already been introduced, our underlying perspective hasn't shifted; we don't anticipate any significant alteration to the category's structural path, and in fact we expect Europe adjusted IMS progression to be roughly consistent with the group growth rate during 2024. Europe is also a key region when it comes to innovation. LEVIA zero-tobacco HTUs became available in the Czech Republic during mid-October via limited channels, and the early response has been encouraging. We intend to expand the Czech rollout more broadly later this month, along with additional market launches during this year. Turning to Japan, the heat-not-burn segment now accounts for nearly 40% of the overall industry, with IQOS fueling that expansion and surpassing 8.5 million adult users. During Q4, the adjusted total tobacco share for our HTU brands rose 3.1 points to 27.6%, while off-take share exceeded 34% in Tokyo. Adjusted IMS volumes climbed 14.5% year-over-year for 2023 and 13.4% during Q4 by itself, hitting a record high of nearly 10 billion units on a four-quarter moving average. That kind of remarkable growth in a market where category penetration is already elevated stands as clear evidence of IQOS's sustainable potential globally. HTU shipment volumes went back to a more normal state in the fourth quarter relative to a difficult prior year inventory comparison, after the shift back to sea freight was largely completed in Q3; on top of robust IQOS share gains in developed countries, we keep seeing highly promising growth in low and middle income markets. This slide spotlights a selection of Q4 key city off-take shares spanning markets in Eastern Europe, Africa, Asia, and Latin America. Egypt remains impressive, with Cairo off-take share climbing plus 3 points to 9.4%, and we're also seeing encouraging results elsewhere in the region, including Morocco and Lebanon. Indonesia likewise made notable progress in its capital city, particularly considering limited commercialization. We keep observing dynamic off-take volume growth throughout these important future markets, and the city shares toward the right side of this chart signal the exciting potential. Although we've already addressed the margin dynamics on combustibles, our 2023 commercial performance was extremely strong, with organic top line growth of plus 5.5%. That mirrors both solid pricing, with notable contributions from Germany and Indonesia, and positive share performance within a resilient international category. Our cigarette category share was up plus 0.1 points in Q4 and plus 0.2 points in 2023, with notable contributions from Egypt, Poland, and Turkey. While it's nice to be helped by rivals' supply issues in Egypt—something that could settle down in 2024—we still hit our long-standing goal of steady category share once you strip that out, even with IQOS eating into our own numbers; that matters because being number one in combustibles is what lets us move as many people as possible over to smoke-free options. That combustible share result, paired with IQOS's built-in growth, pushed our international cigarette and HTU share up by 0.6 points for the whole year. As I've said before, our leading position in smoke-free products hands us a powerful base for lasting share gains, along with better unit economics. Before we get to the 2024 outlook, let me take a quick look back at how strongly we've delivered across the last three years, even with quite a few major headwinds. That showing was plainly better than our currency neutral 2021/2023 targets of over 5% organic top line and over 9% bottom line growth, helped by volumes rising overall; over the coming three years we're aiming for equally strong volume delivery, a plus 6% to 8% organic net revenue CAGR, and a bigger jump in organic operating income growth to plus 8% to 10%; we're targeting an adjusted EPS CAGR of plus 9% to 11% ex-currency growth at constant 2023 corporate tax rates, which includes a rise in net financing costs that leans toward the first year of the period, in 2024. Okay.

Emmanuel Babeau

executive
#5

That leads me to what we expect for 2024. We're anticipating a significant step up in smoke-free results, spanning IQOS shipment volumes, the net revenues of smoke-free products, and gross profit. Our projection is the largest absolute rise ever for HTU adjusted IMS volumes, translating to percentage growth of 14% to 16%. That figure accounts for an estimated roughly 2 billion unit hit tied to consumer adjustment following the EU characterizing flavor ban I brought up earlier, plus basically flat off-take in Russia. On shipments, our goal exceeds 140 billion units, though this depends on the typical unpredictable factors around shipment timing, launches in new markets, and possible supply chain interruptions like what's happening right now in the Red Sea. Shipment growth rates will of course track adjusted IMS eventually, yet inventory levels could come in somewhat below 2023, since ILUMA launches are now largely finished and there's room to optimize working capital. For U.S. ZYN, we're looking for continued outstanding volume expansion to roughly 520 million cans. We've also sped up our capacity expansion initiatives to back this additional major volume increase and to keep inventory in check, since it's naturally influenced by how fast we've been growing lately. With such a robust picture for IQOS and ZYN, we anticipate an acceleration in organic smoke-free top line growth versus 2023, landing near $15 billion in net revenues at current exchange rates. That underpins a total PMI projection of plus 6.5% to plus 8% organic net revenue growth, which includes a fourth straight year of total volume growth along with mid-single digit combustible pricing. We're also calling for faster smoke-free gross profit growth compared with the organic plus 19% we achieved in 2023, driven by IQOS profitability growing and ZYN's superb economics persisting. Smoke-free should once again account for the bulk of our forecast organic OI growth of plus 8% to plus 9.5%, especially considering the persistent cost pressures and negative geographic mix in combustibles that I referenced. That of course points to organic margin expansion, even after accounting for the continuing technical dilution effect from third-party manufacturing in Indonesia. We expect a substantial organic gain in overall gross margins once technical impacts are excluded, with currency having a very small effect on adjusted OI margins. This outlook incorporates sizable capability investments in the U.S., yet as we said at Investor Day, we still anticipate delivering strong double-digit operating income growth in that market. As we highlighted at last year's Investor Day, we foresee higher net financing expense in 2024 as debt gets refinanced at elevated rates. Our forecast range is $1.3 billion to $1.4 billion, versus $1.1 billion in 2023. We're also assuming a greater effective corporate tax rate, reflecting Russia's suspension of certain double tax treaties along with earnings mix. Together, these tax and interest items affect our currency neutral adjusted diluted EPS growth projection by roughly 2 percentage points. So based on that, we're projecting growth in currency neutral adjusted diluted EPS of 7% to 9%. That puts adjusted diluted EPS in a range of $6.32 to $6.44. That figure accounts for an unfavorable currency hit of $0.11 at prevailing rates. Importantly, it also reflects a net favorable impact of $0.13 tied to revaluing monetary balances in hyperinflationary economies during 2023, weighted toward the second half comparison. Now, looking at how 2024 should take shape quarter by quarter, we're expecting solid double-digit growth in adjusted IMS HTU growth each quarter, which backs our full year forecast of 14% to 16%. For Q1, we're forecasting a strong overall performance with HTU shipment volumes between 31 billion and 32 billion, plus continued strong volume growth from ZYN. We anticipate organic top line and operating income growth will be broadly in line with the full year outlook, which implies organic margin expansion consistent with the full year. We're projecting strong Q1 currency neutral adjusted diluted EPS growth of 7% to 10%. That translates to a range of $1.37 to $1.42, including a negative currency variance of $0.10 at prevailing rates, with currency comparisons getting better in the second half as we lap the Argentina impacts from 2023. Our business is still highly cash generative. That said, the $9.2 billion in 2023 operating cash flow came in lower than expected. The reasons were currency effects on net earnings, including the Argentine peso devaluation, other year-end currency impacts, and working capital needs that were higher than expected. In 2024, we're targeting between $10 billion and $11 billion in operating cash flow at prevailing exchange rates, subject to working capital requirements. We keep prioritizing investment in innovation and growing our smoke-free portfolio. For 2024, we expect capital expenditures of roughly $1.2 billion, including the ZYN capacity expansion I just referenced. Deleveraging is still a key priority for us. As expected, our 2023 net debt to adjusted EBITDA ratio was around three times, given the 2023 purchase of the remaining Swedish Match minorities and the final U.S. IQOS payment to Altria. We're targeting much better progress of 0.3 to 0.5 times deleverage in 2024, driven by continued EBITDA growth and strong cash flow generation. We continue to target a ratio of around two times by the end of 2026, with buybacks to be considered once we've confirmed we're on track. Finally, our commitment to our progressive dividend policy is unwavering and in line with our long-term commitment to return cash to shareholders. I'll now turn it back to Jacek for concluding remarks.

Jacek Olczak

executive
#6

Appreciate that, Emmanuel. Now I'd like to walk through what matters most strategically for us in 2024. The first item is backing IQOS's continued upward trajectory via ongoing innovation; that means using the ILUMA rollout to drive the biggest possible increase in users, and pushing further innovation across devices as well as consumables. The second is keeping ZYN's impressive expansion in the U.S. going, underpinned by focused commercial spending, capacity build-out for the long term, and organizational infrastructure, all of which will benefit IQOS too. Beyond America, our plan is to keep building out the integrated multi-category proposition we offer adult nicotine users, with additional ZYN launches and, in the markets where it makes sense, our VEEV e-vapor range. Naturally, for IQOS in the U.S., 2024 stands out as a pivotal year. Although getting IQOS ILUMA launched is what matters most, we're also getting ready for the initial city tests of the IQOS 3 blade product, which begin in Q2 of this year. Through these limited pilot launches, we'll be able to try out various elements of commercialization and bolster our push toward commercial success at scale once ILUMA receives authorization. We don't have anything new to share regarding the anticipated PMTA timeline, but the patent settlement agreement we announced last week clears the way for commercializing both blade and induction products, lowering the risk of patent-related disruption, and lets us tap the scale, optimized cost and flexibility of our global supply chain. On combustibles, our aim stays fixed on holding a stable category share over the long run even with IQOS cannibalization weighing on it, while making sensible pricing moves that contribute positively to profit. When it comes to capital allocation, our priorities couldn't be clearer. We'll keep putting money into growing smoke-free products, and our dedication to the dividend will not waver. With Swedish Match now part of the group, bringing down leverage stays our primary balance sheet goal. On sustainability, we intend to maintain our strong momentum, covering initiatives tied to product impact such as preventing youth access and dealing with post-consumer waste. Last, and crucially, we stay devoted to reshaping the tobacco harm reduction landscape by offering better alternatives to adult smokers who'd otherwise keep smoking, and by championing regulations grounded in science. We'll go deeper on a lot of these subjects at the CAGNY conference, which takes place in two weeks. That brings today's presentation to a close. All told, the business turned in a strong 2023 performance despite meaningful cost headwinds, fueled by structural smoke-free momentum. IQOS's continued outstanding results and ZYN's extraordinary growth cemented their standing as leading brands with outstanding equity. Together with our unmatched commercial and innovation strengths, this gives us a powerful platform to speed up our smoke-free future as we widen our portfolio and extend our reach to adult smokers. We see 2024 as a year when smoke-free products grow faster, and we stay confident in our growth targets for 2024 to 2026. There are exciting opportunities for us in the U.S. and internationally, and we are fully committed to seizing them as we move toward our goal of being sustainably smoke-free by 2030. Last but not least, the robust expansion we foresee, combined with a business that produces a great deal of cash, supports our capacity to bring down debt even as we give money back to shareholders. Thanks; Emmanuel and I would now be glad to take your questions.

Bonnie Herzog

analyst
#7

Hello, everybody. I'd like to pose a broader question regarding the year. Initially, your guidance for FX-neutral EPS growth in '23 was 7% to 9%. However, you ended up closing the year much more robustly, with reported currency-neutral EPS growth of 11%. Looking back, which key areas exceeded your original projections? Then, when considering this year, you're again starting with guidance of 7% to 9% FX-neutral EPS growth. So I'm just attempting to grasp how cautious that might be, particularly given your 9% to 11% midterm growth objective?

Jacek Olczak

executive
#8

Regarding 2023, Bonnie, the momentum we possess in the category within Japan truly deserves special mention. Even though IQOS holds a very substantial portion of the segment, as you're aware, where we perform well beyond our segments, I believe we accounted for roughly 80% of all segment growth in Japan. That's quite impressive. Japan leads in the smoke-free transformation. We're nearing the 10-year anniversary of IQOS in Japan; and if I simply observe how the category keeps expanding in Japan over recent weeks, I think in the Tokyo region, smoke-free products have now roughly surpassed the cigarette category's size; so if IQOS keeps contributing to this remarkable growth after 10 years, that truly merits highlighting. Obviously, ZYN and, as we've made clear, we were very eager and delighted to complete the Swedish Match acquisition, which introduces a crucial component to our alternative smoking portfolio, the pouches, and clearly establishes a strong entry point for us into the U.S. market, and ZYN is evidently exceeding their forecasts. What matters greatly is that we occasionally hear, quite justifiably, discussions about certain unintended effects related to product use. I'm extremely pleased that both IQOS and ZYN are actually fulfilling their intended purpose, namely targeting adult smokers in the U.S. over 21 years old. We're all acquainted with CDC data, under 80% youth usage, and the same applies to IQOS internationally; so we have a solid — in my opinion, we have a highly sustainable, growing pair of outstanding smoke-free product offerings, and we're also striving here to stay very concentrated from a financial standpoint concerning the e-vape. So at present, if we project this into 2024, I believe Japan maintains good momentum. ZYN in the U.S. keeps up this momentum. Europe is performing very strongly indeed. Yes, we have this distortion, perhaps potential headwinds arising there; we distinctly highlighted the $2 billion potential effect from the EU flavor ban. Beyond that, though, these main markets matter a great deal when it comes to margin expansion — they're clearly contributing positively. And I'm not trying to paint a downbeat picture about the rest of the world. Still, something worth keeping in mind: now and then, questions come up about how IQOS is growing and so forth. You'll recall that at Investors Day, I stated it plainly. IQOS has just completed 10 straight years of tremendous growth, even though we basically had no growth available to us in Russia and Ukraine. And looking back, Russia by itself was delivering — it depends on which stretch of time you look at — but comfortably more than 4 billion, perhaps as much as 5 billion annually in category growth. So we ought to view that trajectory with this in mind, and it leaves me feeling even more assured about the 3-year outlook we've given.

Bonnie Herzog

analyst
#9

All right. Thanks for that. It was useful. Next, I'd like to dig a bit deeper into the margin picture. I'm hoping you can give us some additional detail regarding your margins during Q4, particularly within the Americas, since they actually came in negative there. My assumption—and I believe you flagged this—is that one major factor behind that is the money you're putting in ahead of the IQOS relaunch happening in the U.S. in May. Given all that, how should we be thinking about operating income growth for the Americas this year? Is it going to stay negative? And then, when we look at the whole of '24, for the company overall, your guidance for FX-neutral revenue growth along with operating income growth does suggest operating margin will expand. So could you perhaps speak to what you expect for gross margin and OpEx against that backdrop?

Jacek Olczak

executive
#10

Yeah, Bonnie, Emmanuel can add a bit more detail here. In my view, for the Americas segment, what pushed margins lower was more the effect of the Argentine devaluation rather than anything happening in the U.S. market. As for the U.S. market specifically, sure, there's added investment going in to keep backing ZYN's growth, plus ZYN's expansion, and also to get the Swedish Match organization—or Philip Morris International's U.S. organization—ready to be able to take on IQOS shortly and clearly have those organizations positioned for both the opportunities and the challenges of the U.S. market. So some of those investments are already moving through the P&L even before the IQOS commercialization process begins. Emmanuel, would you like to?

Emmanuel Babeau

executive
#11

Yeah, just to add on — to address what you asked, Bonnie, and to build on Jacek's points about what's driving the better-than-expected results for '23. Obviously, like I said, there's a really strong volume dynamic on the commercial side, if you will. But we've also been quite happy with how our margin has developed on our smoke-free product. And right now we're seeing margins on both IQOS and ZYN sitting above the average margin on CC. We're making headway on IQOS profitability, and we had some price increases in Q4 overall. So that was the plan, but it's playing out perhaps even a little better than we anticipated, and we expect that to keep going in Q4; and from that angle, I mean, obviously, the U.S. is a fantastic market. We've talked about how ZYN's margin in the U.S. is best-in-class within our product portfolio; so make no mistake, even though we will indeed keep investing in the U.S., the U.S. is going to be super nicely accretive across all parameters of our P&L — at the level of, of course, revenue growth but also when it comes to margin evolution and operating income. And we reflect the fact that we talk about double-digit growth and very strong double-digit growth. The U.S. is a very powerful contributor to our financial performance.

Bonnie Herzog

analyst
#12

All right. Emmanuel, let me just get one thing straight, if I can. For this year, you're looking at gross margin growth, and maybe operating margin growth too? Going by your guidance, that points to operating margin.

Jacek Olczak

executive
#13

That's right. We certainly do, Bonnie. Yes.

Bonnie Herzog

analyst
#14

Okay, all right, thanks.

Gaurav Jain

analyst
#15

Hello, good morning. I have two questions. First, I just want to clarify the impact from the Argentinian peso. This year you have a $0.19 impact, tied to balance sheet revaluation. And on the slide, the Argentinian peso rate you're using equals the spot rate. So no additional balance sheet revaluation downward should occur, meaning there's an automatic $0.19 benefit to EPS. Doesn't the math work that way?

Jacek Olczak

executive
#16

Well, naturally, we can't speculate about any additional peso devaluation. The truth is the dollar-terms amount has been substantially lowered by that most recent devaluation. So any further devaluation would hit a far smaller amount. I don't know if additional devaluation might occur. Honestly, we can't predict that sort of thing. What you need to factor in is that the basis has been — in fact, essentially with the December devaluation; thus any additional devaluation would hit a smaller base in Argentinian peso.

Gaurav Jain

analyst
#17

Sure. Perhaps I can raise that as a separate item. My second question concerns ZYN. There's been a lot of talk out there; Chuck Schumer made a statement. Many investors are worried, believing that regulation is on the way, and that flavors will be prohibited. So how do you intend to stay ahead of this whole possible controversy that might develop surrounding ZYN?

Jacek Olczak

executive
#18

Yes. So what we've seen these past few weeks, I heard plenty of discussion about Brazil across social media and more broadly on the Internet and in the media. My view is, look, ZYN has been present in the U.S. market for 10 years, right? And when you examine the figures, the CDC's most recent data regarding underage use, and so on, it remains very low. I believe it's 50%, which is the lowest of any nicotine product and also of other products where some significant restrictions are in place. I think we're aware of Swedish Match's marketing practices, and we took this extremely seriously at the time of the acquisition of the (inaudible); we stated that the alignment with Service Match wasn't just about their pursuing the smoke-free path, but also about their having a highly responsible and disciplined approach to marketing, as we do with IQOS, with heat-not-burn and internationally; we've contacted the handful of individuals who have been most outspoken in these discussions with the general consumer, and also the FDA, and I think the facts differ from what is sometimes being — attempts to be the positions taken in the media. So the product is assisting adult smokers with very rigorous age verification. Naturally, when it comes to discussions among adults on social media, that's getting a bit — well, moving ahead, frankly speaking, into territories where we wouldn't have control. ZYN isn't using any paid ambassadors or whatever it's called on social media; so we believe what we're doing is putting forward the right product in terms of the potential for harm reduction, where the product rests on a science-based position and the risk reduction continuum, frankly speaking, it is the best nicotine alternative to any other nicotine product, very much obviously compared with the cigarette. We have a pending PMTA with FDA and feel the science is very strong and very conclusive on that point. So I feel very confident. From the very start of our transformation, solid Swedish Match, we placed the marketing team and very much youth protection very, very high on our agenda; so I think that gives me the confidence that, as I said earlier in response to Bonnie's question, we have progress, phenomenal growth on the products, which are delivered in a very sustainable manner to adult smokers.

Pamela Kaufman

analyst
#19

Morning. I'd like to ask about ZYN too. In the U.S., it has experienced incredible expansion. Could you explain what's behind the faster growth of ZYN in the U.S.? Also, are there specific areas where growth is stronger? And regarding the ZYN guidance, it suggests roughly 35% growth in U.S. shipments, yet that appears cautious considering the momentum we've observed. So is there anything that might hold back ZYN's growth outlook compared to what we're seeing?

Jacek Olczak

executive
#20

Yeah. As you might remember from our Investors Day, when it comes to ZYN — thinking about the smoke side and where the adult consumers originate — we're drawing quite effectively from combustible cigarettes, clearly, and from the broader categories too, such as tobacco-containing pouches, Swedish snus and products like those, along with pulling in users from the vape segment. So an increasing number of adults are becoming aware of it, and they appreciate how convenient it is to use in Brazil. Another lens on ZYN is that it represents a natural innovation, or an extension, of Swedish snus — the tobacco-containing pouch. Naturally, as we're aware, certain individuals may have felt uneasy about having tobacco inside the pouch. Certain optical hygiene items come with restrictions and so forth, and ZYN stands out as a product that — appears more pristine, being white in color, and it has no tobacco in it, which could have been a — could be something that turns off certain buyers. That's really all I can offer on that. In my view, this product is on a solid path. Within the United States, we're dealing with a huge market that includes a mature e-vape segment, clearly a still quite substantial combustible cigarette segment, plus numerous additional oral tobacco formats, making it a great place for ZYN to draw from, since it resonates with those groups. As for what you mentioned about the projected account count, that's obviously tied to the outlook we've given for the coming year. That slight pattern in the U.S. is something we know quite well. Is it possible ZYN delivers an upside surprise? Yes, it could — however, the guidance rests on a set of assumptions, correct? What I mean is this is a worldwide operation spanning multiple categories, and certain headwinds exist that we can already see. Whether much has actually come to pass, I can't say for certain, but I believe prudence plays a role here: at this point early in the year, you identify those factors and stay cautious — while recognizing there are also favorable elements and tailwinds we clearly understand. The faults from year-end will carry into Q1. From my perspective as a player, confidence gets built up progressively over the course of the season. Right. And Pam, just to make the guidance clear here, what we're putting forward is a year-on-year increase that would be comparable to what we've already been seeing when it comes to overall volume growth — not a large percentage-type year relative to '23 and '22. So the gains in volume are similar in character. This connects to a deceleration in that growth rate. Whether we keep rising past the projection we currently have, we'll have to see for now.

Pamela Kaufman

analyst
#21

All right, thank you. That's clear to me. Now I'd like to ask about the patent settlement involving BAT. Could you walk us through what that means? I'm aware that you've put money into U.S. manufacturing capacity for IQOS. In what way does this settlement affect your capacity to bring product into the U.S.? And will your approach to manufacturing shift as a result?

Jacek Olczak

executive
#22

Essentially, what it does is let us now link IQOS in the U.S. up with the supply chain as well — the same international supply chain that's been running since day 1, enjoying every advantage that comes with economies of scale and so forth. So clearly, as a risk-mitigation approach, we'd been pursuing alternate production inside the U.S. at the same time, yet that is plainly the initial plant, the initial volumes; it would plainly lead to higher or inflated costs on both the devices and the HeatSticks, and some time will pass before the U.S., standing on its own, could reach the identical degree of cost advantages, so to speak, that we enjoyed internationally. So from our standpoint, it opens the way for IQOS, top blend and ILUMA; thus we're introducing a great deal of — or rather eliminating, I ought to say, that ambiguity as of today and moving ahead. And IQOS, being that it's U.S., is simply one more market that we've added to the geographic roster of IQOS markets from day 1, and it will have access, as I mentioned, to the product pipeline along with its economic cost advantages as an international market. So from our perspective, it's really clarity and speed that we obtain via this agreement. And clearly, as everyone is aware, the patent litigation space carries a significant level of unpredictability; and we operate a very large business and intend to have an even larger business now that the U.S. is included, and that clarity plus the forward visibility matters greatly, which I think also matters greatly to investors.

Mirza Faham Ali Baig

analyst
#23

Hey everyone. Afternoon to you all. Thanks for taking my questions. I've got a few myself, if that's okay. To start, your guidance points to yet another strong year, with in-market sales for heated tobacco rising at a mid-teens pace. You've said Europe will land inside that band. In the past, Europe has performed a bit stronger. Which markets create that gap, letting you still reach mid-teens growth? Could you speak to the bigger markets? And inside that, do you count any help from Taiwan or Saudi Arabia, which you brought up? And what's the outlook for the U.S., too, please?

Jacek Olczak

executive
#24

Let me begin with the U.S. For the U.S., we're going to run a test market on IQOS three point — the item we've called the IQOS 3.0 blade product, which for us is honestly the expensive route, and we keep hoping for more clarity from FDA concerning the PMTA MRTPA for IQOS, since that would let us speed up a wider, more nationwide form of commercialization. So for 2024, what we've built in for IQOS volume contribution from the U.S. is extremely small. Our view isn't that this tests the engine, the commercial side, or the consumer phasing kind of approach; instead it's about lowering the present version of the product across the full scope. We've assumed — we made certain assumptions about opening markets where IQOS currently isn't permitted. The trade not on the list is clearly Taiwan. Fine, those are among the assumptions, and we could prove right or wrong, yet these are what we went with. Naturally it depends on how fast some regulatory choices happen and laws get passed, and so on. Now on Europe, look, although I think and history has demonstrated, with flavor-style regulations across various categories and various geographies, that across a stretch of time they don't carry much effect on the dollar. But we're entering a stretch where certain markets, or markets, will be putting these regulations in place. I believe one must be careful that some distortions could appear. What I mean is they issue guidelines, and if these stay transparent, they still leave you potential alongside a headwind, which we factor into the volume outlook for IQOS, though we'll need to watch where this plays out. Not plays out — I think it comes down to who, and then we ought to discuss it. Beyond that, the underlying IQOS growth, if I check the value of a share evolution, basically, our European market remains quite strong even though, very much in Central Europe, there may be greater pricing competition from other heat-not-burn players. Yet we also face very strong price competition, extremely strong price competition, I should say, on both devices and consumables, consumables in Japan. And across that stretch, IQOS handles this very competitive pricing landscape—which can be aggressive at times—quite effectively. So that's basically the situation we're in. Germany is expanding quite well. Italy keeps up a really robust growth trajectory. Once again, Spain serves as the main engine. We're making—we're beginning to make meaningful headway. So that's all from my side.

Mirza Faham Ali Baig

analyst
#25

Thanks. Then I have one more item, if I may. You anticipate an acceleration in smoke-free for 2024, yet that isn't showing up as faster growth in consolidated net revenue for 2024. Do you think combustibles will perform more weakly in 2024? Is that where the gap comes from?

Jacek Olczak

executive
#26

Yeah. I mean, look, this is the combined — right now, as we begin the year, the combined projection for revenue at the group level covers combustibles, oral, and, clearly, heat-not-burn. There are a handful of other smaller items; yet during the prior year we succeeded in achieving a very robust price/mix benefit. Again, I'd say it's reasonable to expect that the force behind a price variance might not be replicable in the current year; however there is clearly room on pricing, which we factored into, or incorporated within, the guidance. Look, with certain of these matters, we require somewhat greater visibility before we can begin raising our confidence. I remain of the view that when I set side by side what Philip Morris is producing today, there were a number of years when we pushed the top line for revenue past 7%. And I recall quite clearly the period when transformations began, back when it was 3% to 5%; at present I'd say quality is what matters to us, and that's where we place a great deal of focus — we don't merely aim to lead revenue expansion in a lasting way, but clearly what's important is the caliber of that revenue expansion. So when you have 3-year total group volumes beginning above — no decrease, not even level, but rising — and then you layer pricing on top and handle it by concentrating on steering clear of the danger of some trading down, and so on, I'd argue the 7% is present; well, revenue growth beyond 7% is, qualitatively speaking — not only in nominal growth terms — I would say that's the whole of EBITDA.

Emmanuel Babeau

executive
#27

To build on Jacek's remarks, yes, we're factoring in that 2023 was an unusual year on pricing, with nearly 9% growth in the combustible portfolio, and our plan is not to do that again. For 2024, our guidance points to a mid-single-digit price increase. Naturally, that's going to affect and change how our revenue grows in the combustible business.

Callum Elliott

analyst
#28

Hello, and good morning. I appreciate you taking the questions, everyone. To kick things off, I'd like to focus on disposable vaping items. It's clear these goods achieved tremendous traction across the U.S. throughout 2023, and in the U.K. as well, which pushed a sharper drop in volumes for combustible cigarettes in both of those markets. Naturally, your combustible cigarette operation in those two countries isn't large — and in the U.S., it's essentially absent. So up to now, there hasn't been much of an effect on your company. My question, though, is this: why haven't we witnessed comparable traction for such items in the countries that matter greatly to your company, especially within the EU? And might this pose a danger to your company during 2024?

Jacek Olczak

executive
#29

Are you referring to a danger to our company stemming from e-vape goods? Well, several elements are involved, correct? For starters, I'd say the e-vape goods category is being disposable; it isn't disposable. Its emphasis, when it comes to what's offered and to innovation — to put it plainly — is really on the flavors, correct? After that, we frequently overlook that the heart of the smokers' market, country by country, with only a handful of exceptions, is very much — if I were to describe it — a conventional tobacco-style experience in terms of flavor and so on. Consequently, this produces something closer to dual usage, or use on occasion. Yet I believe that for certain smokers — and our IQOS experience teaches us this — it genuinely sparks a desire to give it a try, while simultaneously creating a hurdle when it comes to adopting a full-time kind of switch; so that's one element, all right? And beyond that, clearly, there are additional elements in play.

Callum Elliott

analyst
#30

Sure, I get that. But why is it — in America and Britain, that hasn't really held these products back from succeeding across the last 12, 18 months.

Jacek Olczak

executive
#31

It comes down to results, and where the attention sits, correct? Since the U.K., just like the U.S., was out in front — if my memory of the history serves — leading the way in this category, partly drawn in, I'd say, by the margins sitting underneath in the CC category. So clearly, folks gravitate toward substitutes in markets that generate that kind of margin potential, along with comparatively greater latitude to discuss such products. As you're aware, across Europe largely, and likewise internationally in certain nations, these products aren't especially — how should I phrase it — greeted with warmth. So let's set the hybrid action principles to one side. Yet other perspectives and viewpoints are in play. Look, we recognize that we're stepping into a e-vape category, though we aim to stay quite disciplined, or focused, I'd say, and slipping into this category is quite simple without much of a route toward lasting profitability. And we don't wish to divert the company away from other chances we're chasing, which, as we see it, are more durable and provide a solid foundation for margins and the profitability beneath. But once we launch with this product — Italy, Czech, a handful of additional markets — our offerings, even though we arrived somewhat late into the — from the standpoint of category history, and after that we've captured double-digit shares in this market within a stretch of under 12 months or thereabouts. So that also reveals to you there's plenty of missing loyalty out there. There's plenty of — yes, I realize we observe the volumes, yet there's plenty of trial. I shouldn't dismiss the category and the pouches judged by how they perform in the U.S. And consequently, by nature, the consumer shows greater loyalty, greater focus, greater discipline in the way they move through it as well.

Callum Elliott

analyst
#32

All right, and then a second question that ties in, though it might be a bit more on the philosophical side. Across quite a few markets — and particularly in the U.S. — when it comes to certain of those disposable vape items, what we've noticed is the emergence of, I'd call it a two-tiered marketplace taking shape, with large established companies like yours that are required to follow the rules and keep themselves to particular standards, advertising solely to people who already use nicotine — and I'd assume everyone here has seen that ZYN video from last week — yet simultaneously there's this other group of smaller upstart firms that appear to be essentially doing as they please, frequently unlawfully, while achieving tremendous success in the market and drawing in tons of customers. So my question, I suppose, is whether you believe this two-tiered setup that appears to be emerging across multiple markets structurally undermines how appealing your company and your brands are, given that you seem to be stuck competing on a field that isn't level?

Jacek Olczak

executive
#33

Well, look, clearly, a business such as ours doesn't even entertain the thought of doing anything that would violate or step over the regulatory line, or even, I'd add, what society expects. So clearly, I mean, our capacity to appear before you — that's not what you're asking — is vastly different from that of certain other players or market participants, particularly those lacking any 10-year or 15-year perspective, since theirs is basically a hit-and-run sort of business. And I believe we're aware of what took place, or what's currently taking place, in the U.S. There is, as I grasp it, some market discipline now in motion. But honestly, it's far overdue, because a great deal of — excuse my wording — chaos has been produced in the market owing to the fact that regulators, law enforcement and the other bodies designated for these purposes moved somewhat slowly. And honestly, I'd say it's a carbon copy of what we've had for years, and still do in certain locations, more or less in the cigarette market, in the form of unlawful participation in that market. It isn't just marketing conduct, but products too, product standards — every one of these matters generates total distortions in the market at the cost of legitimate category producers and likewise pulls the discussion away from how much further we could advance and achieve reductions, steering it instead toward matters that ought to be remedied with relative ease.

Callum Elliott

analyst
#34

Okay, thanks, Jacek.

Jacek Olczak

executive
#35

Thank you.

Matt Smith

analyst
#36

I believe you were next in line to speak, Emmanuel, and I had a follow-up regarding the amount of investment baked into the 2024 guidance. When we look at what's expected for gross and operating margin improvement on an organic basis, could you discuss where you're anticipating a meaningful step up in incremental spending? A year ago, you highlighted $150 million in explicit investments, with roughly $75 million of that in the U.S.; it appears that ZYN's growth would let you raise that spending level while still hitting your double-digit profit goals in that market.

Jacek Olczak

executive
#37

Right. Much depends, clearly, on our target of adjusted live growth exceeding revenue growth. Clearly, we're factoring in some margin improvement. That said, I believe we'll have sufficient resources to back that revenue growth. So it is — had we decided to halt all investment entirely, clearly, the expansions on a wide growth would be far larger, margin expansions would be far larger, but we are — that's not what our strategy reflects. So once we run it at scale and we build, as the consumer does there, the scale in the U.S., the revenue over there is quite substantial, at least by market standards. And with the revenue we bring in from a small crew, plus combustibles internationally at that kind of revenue growth rate, I think we have room to fund the investments needed for today's and tomorrow's growth while still enabling margin expansion; we've also noted some inflationary pressure here. And I think, particularly on the combustible side, I — we're assuming 2024 is essentially the final year of this extraordinary period of inflation under pressure. And starting in 2025, put differently, we ought to begin seeing relief when it comes to COGS pressures, and this concerns delivering some other materials; and I think each additional IQOS and each additional ZYN obviously needs proportionally less investment than the first IQOS and the first ZYN. So, I mean, the scale offered going forward, there's a chance to support the margin.

Matt Smith

analyst
#38

Thanks, Jacek. I'll stop right there and hand things over.

Jacek Olczak

executive
#39

Thanks, Matt.

James Bushnell

executive
#40

My apologies. Just before we wrap up, a reminder that on February 21 we'll be presenting at the CAGNY conference, and we'd love for you to attend, whether you come in person or virtually. Thanks once more for being with us today. Should any follow-up questions come up, please reach out to the Investor Relations team, and I hope your day is a great one.

Jacek Olczak

executive
#41

Thank you, all. Speak to you soon.

Emmanuel Babeau

executive
#42

Thank you.

Operator

operator
#43

That wraps up the call for today. We appreciate everyone joining us. At this point, you're free to hang up.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.